FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

BioCryst Pulls IND for HCV Investigational Drug

[ Price : $8.95]

BioCryst Pharmaceuticals withdraws its IND for the antiviral nucleoside, BCX5191 after FDA expressed concerns about its preclinica...

Navidea Resubmits Lymphoseek NDA

[ Price : $8.95]

Navidea Biopharmaceuticals resubmits its Lymphoseek NDA to FDA to answer agency questions about third-party cGMPs.

Generic Drug Adverse Event Liability Still Evolving

[ Price : $8.95]

Attorney Steven Casey says the law remains unsettled on the question of who is liable for adverse reactions patients experience wh...

Stakeholders May Suggest IMDRF Work Items

[ Price : $8.95]

CDRH associate director for international affairs Kimberly Trautman says that medical device stakeholders worldwide have an opport...

Advisors Asked for Anthrax Drug Opinion

[ Price : $8.95]

FDA asks its Anti-infective Drugs Advisory Committee to comment on the efficacy and safety of Human Genome Sciences raxibacumab fo...

Ameridose Compounding Firm Recalls Drug Products

[ Price : $8.95]

Ameridose, the sister company of troubled New England Compounding Center, recalls all unexpired products remaining in circulation ...

Biogen Idec Plans BLA for Clotting Factor

[ Price : $8.95]

Biogen Idec plans to submit a BLA in the first half of 2013 for a long-lasting recombinant Factor VIII Fc fusion protein (rFVIIIFc...

CDRH Puzzled By Increasing Class 1 Recalls

[ Price : $8.95]

CDRH says it is puzzled by an increase in Class 1 medical device recalls seen over the past four years.

Learned Intermediary Helps Florida Failure-to-warn Defense

[ Price : $8.95]

Attorney Mimi Davis says the learned intermediary doctrine may be a defense in failure-to-warn cases being tried under Florida law...

Gilead Phase 2 Study of HIV Drug Meets Primary Objective

[ Price : $8.95]

Gilead Sciences says a Phase 2 clinical trial evaluating tenofovir alafenamide fumarate for treating HIV-1, has met its primary ob...